Update on cancer therapeutics最新文献

{"title":"Plasma cell dyscrasias and leukemias","authors":"Peter H. Wiernik","doi":"10.1016/j.uct.2006.05.007","DOIUrl":"10.1016/j.uct.2006.05.007","url":null,"abstract":"<div><p><span>There has been remarkable progress in our understanding of plasma cell dyscrasias<span><span><span> and leukemias in recent years. New prognostic factors have come to light. Del(1)(p12) and t(4;14) confer poor prognoses on patients with </span>myeloma. COX-2 positivity is associated with poorer progression-free and overall survival in myeloma patients and a role for COX-2 inhibitors in myeloma has been suggested. </span>Thalidomide (400</span></span> <span>mg/day) and dexamethasone (20</span> <!-->mg/m<sup>2</sup><span><span> daily for 4 days) has emerged as first-line treatment for myelomas. Serious toxicities have been recognized, however. The thalidomide derivative, </span>lenalidomide<span> may be more active and less toxic than the parent compound and may replace it. Lenolidomide is also highly active against 5q-syndrome. Bortezomib is at least as active as thalidomide and less toxic, and the two drugs are not cross-resistant. Although marrow transplantation was the standard of care for newly diagnosed myeloma patients, recent prospective randomized studies cast doubt on its role.</span></span></p><p><span><span><span>ZAP-70 and CD38<span> expression have major prognostic impact on outcome of chronic lymphocytic leukemia (CLL). The former may be a stronger predictor of the need for treatment than the presence of an unmutated IgV(H) gene. Although </span></span>fludarabine is highly active in CLL, it may be associated with a higher number of second malignancies than are other treatments. </span>Rituximab has major activity against CLL. However, at standard dose its effectiveness is limited by the fact that </span>CD20 density is relatively low on CLL cells and circulating CD20 binds a significant fraction of administered drug. Either combining rituximab with other agents, or giving it in mega doses, which are safe and highly effective, can overcome these impediments.</p><p><span>Imatinib has revolutionized the treatment of chronic phase </span>chronic myelocytic leukemia<span><span><span> (CML) and markedly decreased the number of allogeneic bone marrow transplants done for this neoplasm. However, the development of rapid resistance to the agent in </span>blast crisis of CML or Philadelphia chromosome-positive </span>acute lymphocytic leukemia<span><span> gives the agent only a minor role in those diseases. More effective tyrosine kinase inhibitors currently under development may prove to be more useful in </span>acute leukemias<span> with the Philadelphia chromosome.</span></span></span></p><p><span>Clofarabine is a successful new drug for </span>acute myeloid leukemias<span><span> of childhood and juvenile myelomonocytic leukemia<span>. Drugs such as gemtuzumab ozogamicin<span>, FLT3 inhibitors and farnesyl transferase inhibitors have been disappointing in acute leukemia. </span></span></span>Histone deacetylase<span> inhibition, especially in combination with proteasome inhibition, may be effective acute leukemia treatment.</","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 4","pages":"Pages 539-567"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.05.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55737633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents of Volume 1","authors":"","doi":"10.1016/S1872-115X(06)00077-6","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00077-6","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 4","pages":"Pages 569-572"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00077-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137128591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soft tissue sarcoma","authors":"M. Austin, R. Andrassy","doi":"10.1007/978-3-662-48590-3_20","DOIUrl":"https://doi.org/10.1007/978-3-662-48590-3_20","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 1","pages":"345-381"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-662-48590-3_20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51373388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the use of antigen-specific T cells for the treatment of cancer","authors":"Cassian Yee ,&nbsp;Herschel Wallen ,&nbsp;Naomi Hunder ,&nbsp;John A. Thompson ,&nbsp;David Byrd ,&nbsp;J. Zachary Reilly ,&nbsp;Deborah Hendricks ,&nbsp;Karla Kenyon ,&nbsp;Lisa Schirmer","doi":"10.1016/j.uct.2006.06.002","DOIUrl":"10.1016/j.uct.2006.06.002","url":null,"abstract":"<div><p><span>In recent years, the feasibility of isolating and expanding antigen-specific T cells for use in clinical trials has been established by several laboratories. The fundamental considerations associated with isolation or enrichment of antigen-specific effector cells in vitro, and the selection, expansion and administration of cellular products with the degree of rigor necessary for clinical trials have been addressed. These can now serve as a springboard for developing strategies that focus on enhancing the survival and function of adoptively transferred T cells. An increased understanding of cellular immunity, and the availability of advanced technologies to generate and monitor antigen-specific T cells, allows investigators to manipulate the immune response to an extent not previously possible. In this review, we describe recent discoveries that contribute to translational strategies in adoptive </span>T cell therapy.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Pages 333-342"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55737861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abbreviations of drugs","authors":"","doi":"10.1016/S1872-115X(06)00061-2","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00061-2","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Pages I-III"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00061-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91995600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Abbreviations","authors":"","doi":"10.1016/S1872-115X(06)00063-6","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00063-6","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Pages VII-X"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00063-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92067436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NSC-Numbers","authors":"","doi":"10.1016/S1872-115X(06)00064-8","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00064-8","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Page XI"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00064-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92140897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright text","authors":"","doi":"10.1016/S1872-115X(06)00060-0","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00060-0","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Page ii"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00060-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137409178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biology and therapy of solid tumors in childhood","authors":"Henk van den Berg","doi":"10.1016/j.uct.2006.05.004","DOIUrl":"10.1016/j.uct.2006.05.004","url":null,"abstract":"<div><p>In children malignancies have characteristics distinct from tumors occurring in adults. For instance, the reported incidence is substantially lower, varying from 90 to 170 cases per 1,000,000 child years. Long-term event-free survival rates above 80% are noted in several tumors. Biology is essentially different; in pediatrics the number of mutations is limited and they are linked with specific malignancies, whereas in adults an accumulation of multiple mutations is assumed. Hereditary factors are noted in several neoplasm's. Although the linkage of syndromes with specific tumors is known for a prolonged time, currently the link with minor congenital anomalies in specific tumor types gets more prominent. Environmental factors related with an increased or a decreased risk of cancer are noted.</p><p><span><span>In this review an update is given on tumor biology and treatment for several tumors, i.e. neuroblastoma<span>, Ewing sarcoma, </span></span>osteosarcoma<span>, nephroblastoma, </span></span>rhabdomyosarcoma<span><span><span>, hepatoblastoma and </span>retinoblastoma. Among the aspects dealt with are the occurrence of </span>spontaneous remissions<span>, I-meta-iodobenzylguanidine (MIBG) imaging and treatment, apoptosis<span> induction, antisense therapy<span><span>, immunotherapy, </span>tyrosin<span> kinase inhibition, stem cell transplantation, suicide gene therapy and anti-angiogenic therapy.</span></span></span></span></span></p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Pages 367-383"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.05.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55737497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abbreviations of chemotherapeutic combinations","authors":"","doi":"10.1016/S1872-115X(06)00062-4","DOIUrl":"https://doi.org/10.1016/S1872-115X(06)00062-4","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":"1 3","pages":"Pages IV-VI"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(06)00062-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137408065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}